Complete financial analysis of Pieris Pharmaceuticals, Inc. (PIRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pieris Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PSB Industries (PSB.PA) Income Statement Analysis – Financial Results
- Internet Thailand Public Company Limited (INET.BK) Income Statement Analysis – Financial Results
- Deltamac(Taiwan)Co.,Ltd (6144.TWO) Income Statement Analysis – Financial Results
- PT Dharma Polimetal Tbk (DRMA.JK) Income Statement Analysis – Financial Results
- Array Technologies, Inc. (ARRY) Income Statement Analysis – Financial Results
Pieris Pharmaceuticals, Inc. (PIRS)
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.81M | 25.90M | 31.42M | 29.32M | 46.28M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 9.88M | 11.38M |
| Cost of Revenue | 41.80M | 2.78M | 2.37M | 46.53M | 55.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.55M | 0.00 |
| Gross Profit | 1.01M | 23.12M | 29.05M | -17.21M | -8.72M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 12.43M | 11.38M |
| Gross Profit Ratio | 2.36% | 89.27% | 92.46% | -58.68% | -18.84% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 125.78% | 100.00% |
| Research & Development | 41.80M | 52.98M | 66.66M | 46.53M | 55.00M | 41.49M | 22.29M | 19.70M | 8.24M | 5.60M | 9.41M | 10.85M |
| General & Administrative | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 280.86K |
| SG&A | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.99M |
| Other Expenses | 13.91M | -8.17M | -3.69M | -3.66M | -26.00K | 1.80M | -2.10M | 119.50K | 10.91K | 3.00K | 6.31K | 0.00 |
| Operating Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Cost & Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Interest Income | 1.85M | 721.00K | 4.00K | 511.00K | 1.71M | 1.96M | 152.00K | 2.32K | 0.00 | 0.00 | 0.00 | 177.13K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95M | 2.32K | 184.65K | 2.65M | 493.94K | 0.00 |
| Depreciation & Amortization | 1.78M | 2.78M | 2.37M | 2.13M | 1.04M | 570.00K | 369.00K | 361.38K | 307.91K | 366.98K | 384.68K | 378.32K |
| EBITDA | -22.76M | -30.50M | -43.37M | -31.61M | -26.12M | -30.26M | -14.23M | -22.40M | -13.37M | -6.83M | 938.50K | -1.80M |
| EBITDA Ratio | -53.17% | -136.29% | -153.24% | -108.43% | -56.43% | -103.99% | -56.28% | -390.33% | -466.25% | -134.11% | 9.56% | -15.83% |
| Operating Income | -29.76M | -43.47M | -51.83M | -33.92M | -27.16M | -30.83M | -14.59M | -22.76M | -13.68M | -7.20M | 553.83K | -2.18M |
| Operating Income Ratio | -69.51% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.33% | -466.62% | -134.17% | 5.61% | -19.15% |
| Total Other Income/Expenses | 5.21M | 10.20M | 6.09M | -3.15M | 1.69M | 3.77M | -1.95M | 122.00K | -173.74K | -2.65M | -487.63K | -140.55K |
| Income Before Tax | -24.54M | -33.28M | -45.74M | -37.07M | -25.47M | -27.07M | -16.54M | -22.64M | -13.85M | -9.85M | 66.20K | -2.32M |
| Income Before Tax Ratio | -57.33% | -128.47% | -145.58% | -126.41% | -55.03% | -93.01% | -65.46% | -388.24% | -472.55% | -183.60% | 0.67% | -20.39% |
| Income Tax Expense | 0.00 | -2.02M | -2.37M | 164.00K | -1.71M | -312.00K | 1.10M | 161.97K | 203.87K | -18.00 | 487.63K | 22.00 |
| Net Income | -24.54M | -31.25M | -43.37M | -37.23M | -23.76M | -26.75M | -17.65M | -22.80M | -14.06M | -9.85M | 66.20K | -2.32M |
| Net Income Ratio | -57.33% | -120.66% | -138.03% | -126.97% | -51.33% | -91.93% | -69.82% | -391.02% | -479.50% | -183.59% | 0.67% | -20.39% |
| EPS | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| EPS Diluted | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| Weighted Avg Shares Out | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
| Weighted Avg Shares Out (Dil) | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Source: https://incomestatements.info
Category: Stock Reports